Skip to content

GeneFrontier ジーンフロンティア株式会社

  • Solutions
    • Koutai Shokunin
      • Overview
      • Price
      • Flow
      • Cases
      • Publications
      • FAQ
    • PUREfrex®
      • Overview
      • Lineup
      • Technology
    • PUREfrex® RD
      • Overview
      • Cases
      • Publications
      • FAQ
    • Drug Discovery
      • Overview
  • Support
    • Downloads
      • Koutai Shokunin
      • PUREfrex®
      • PUREfrex® RD
    • Cases
      • Koutai Shokunin
      • PUREfrex®
      • PUREfrex® RD
    • News
      • Exhibition
      • Campaign
      • Others
    • FAQ
      • Koutai Shokunin
      • Purefrex®
      • PUREfrex® RD
  • Company
    • Intoroduction
    • Corporate Profile
    • Access
    • Partners
  • Contact
    • General Contact Form
    • Koutai Shokunin Contact Form
    • PUREfrex® Contact Form
検索 検索
日本語
English

Cases

  • Home
  • Support
  • Cases
  • Drug DiscoveryPUREfrex® RD
  • Small Molecule projects
  • All
  • Koutai Shokunin
  • PUREfrex®
  • PUREfrex® RD

Small Molecule projects

[2023]

Cyclic peptides are utilized for design of small molecule.

A paper on CTLA-4-binding cyclic peptides and their peptidomimetic small molecules by joint research by GeneFrontier and PRISM BioLab has been published in Pharmaceuticals.

 

No. Target Stage
No.1 CTLA-4 Hit identification
No.2 IL-6 Under screening

(Based on the collaboration with PRISM BioLab)

 

Related Products and Services

PUREfrex RD
PUREfrex® RD
Drug Discovery
Drug Discovery

投稿ナビゲーション

Previous PostPrevious Cyclic Peptide projects
Next PostNext New Biologics projects
  • Solutions
    • Koutai Shokunin
    • PUREfrex®
    • PUREfrex® RD
    • Drug Discovery
  • Support
    • Downloads
    • Cases
    • News
    • FAQ
  • Company
    • Intoroduction
    • Corporate Profile
    • Access
    • Partners
  • Contact
    • General Contact Form
    • Koutai Shokunin Contact Form
    • PUREfrex® Contact Form
  • Recruit
  • Privacy Policy
Copyright © 2025, GeneFrontier Corporation All rights reserved.